Advertisement
Screener

Merck & Co., Inc. (MRK) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

2.2 / 5 stars · 50/112 Roast Me

Merck & Co., Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate

Merck & Co., Inc. (MRK) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate of 3.10% for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-24.

Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology

us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate · last filed 2026-02-24

  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2018-03-31 was 3.40%, a 8.11% decline year-over-year.
  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2017-03-31 was 3.70%, a 2.63% decline year-over-year.
  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2016-03-31 was 3.80%, a 9.52% decline year-over-year.
  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for the quarter ending 2015-03-31 was 4.20%, a 0.00% change year-over-year.
  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2025 was 3.10%, a 3.33% increase from fiscal 2024.
  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2024 was 3.00%, a 3.23% decline from fiscal 2023.
  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2023 was 3.10%, a 0.00% change from fiscal 2022.
  • Merck & Co., Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, expected dividend rate for fiscal 2022 was 3.10%, a 0.00% change from fiscal 2021.
Period endShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 3 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 6 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 9 monthShare-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate 12 month
2025-12-313.10%
10-K · filed 2026-02-24
2024-12-313.00%
10-K · filed 2026-02-24
2023-12-313.10%
10-K · filed 2026-02-24
2022-12-313.10%
10-K · filed 2025-02-25
2021-12-313.10%
10-K · filed 2024-02-26
2020-12-313.10%
10-K · filed 2023-02-24
2020-09-303.10%
10-Q · filed 2020-11-05
2020-06-303.10%
10-Q · filed 2020-08-05
2019-12-313.20%
10-K · filed 2022-02-25
2019-09-303.20%
10-Q · filed 2020-11-05
2019-06-303.20%
10-Q · filed 2020-08-05
2018-12-313.40%
10-K · filed 2021-02-25
2018-09-303.40%
10-Q · filed 2019-11-05
2018-06-303.40%
10-Q · filed 2019-08-06
2018-03-313.40%
10-Q · filed 2019-05-08
2017-12-313.60%
10-K · filed 2020-02-26
2017-09-303.60%
10-Q · filed 2018-11-06
2017-06-303.60%
10-Q · filed 2018-08-07
2017-03-313.70%
10-Q · filed 2018-05-08
2016-12-313.80%
10-K · filed 2019-02-27
2016-09-303.80%
10-Q · filed 2017-11-07
2016-06-303.80%
10-Q · filed 2017-08-08
2016-03-313.80%
10-Q · filed 2017-05-09
2015-12-314.10%
10-K · filed 2018-02-27
2015-09-304.10%
10-Q · filed 2016-11-07
2015-06-304.10%
10-Q · filed 2016-08-08
2015-03-314.20%
10-Q · filed 2016-05-09
2014-12-314.30%
10-K · filed 2017-02-28
2014-09-304.30%
10-Q · filed 2015-11-05
2014-06-304.30%
10-Q · filed 2015-08-06
2014-03-314.20%
10-Q · filed 2015-05-07
2013-12-314.20%
10-K · filed 2016-02-26
2013-09-304.20%
10-Q · filed 2014-11-10
2013-06-304.20%
10-Q · filed 2014-08-07
2012-12-314.40%
10-K · filed 2015-02-27
2012-09-304.40%
10-Q · filed 2013-11-07
2012-06-304.40%
10-Q · filed 2013-08-07
2012-03-314.40%
10-Q · filed 2013-05-09
2011-12-314.30%
10-K · filed 2014-02-27
2011-09-304.30%
10-Q · filed 2012-11-09
2011-06-304.30%
10-Q · filed 2012-08-07
2011-03-314.20%
10-Q · filed 2012-05-08
2010-12-314.10%
10-K · filed 2013-02-28
2010-09-304.10%
10-Q · filed 2011-11-08
2010-06-304.10%
10-Q · filed 2011-08-08
2010-03-314.10%
10-Q · filed 2011-05-09
2009-12-316.30%
10-K · filed 2012-02-28
2009-09-306.40%
10-Q · filed 2010-11-08
2009-06-306.40%
10-Q · filed 2010-08-06
2008-12-313.50%
10-K · filed 2011-02-28

Similar stocks

Stock NameCountryMarket CapPE Ratio
AbbVie Inc. (ABBV)United States$468.180B70.37
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
PFIZER INC (PFE)United States$162.042B31.94
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
JOHNSON & JOHNSON (JNJ)United States$652.528B29.10
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60